N L Edwards

N L Edwards, M.D.

PROF & PRG DIR

Department: MD-MEDICINE CHAIRMAN
Business Phone: (352) 265-0239
Business Email: edwarnl@ufl.edu

Accomplishments

Master of the American College of Physicians
2015 · American College of Physicians
Master of the American College of Rheumatology
2015 · American College of Rheumatology

Teaching Profile

Courses Taught
2018
MDC7200 Medicine Clerkship
2018
MDC7203 Senior Medicine Clerk
2021
PAS5020 Intro to Medicine 2

Board Certifications

  • Internal Medicine
    American Board of Internal Medicine
  • Rheumatology
    American Board of Internal Medicine

Clinical Profile

Specialties
  • Rheumatology
Areas of Interest
  • Gout
  • Granulomatosis with polyangiitis
  • Osteoarthritis
  • Rheumatoid arthritis

Publications

2022
Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response.
Current rheumatology reports. 24(1):12-19 [DOI] 10.1007/s11926-022-01055-9. [PMID] 35167037.
2022
Gout management and outcomes during established COVID-19 pandemic in 2020-2021: a cross-sectional Internet survey.
Therapeutic advances in musculoskeletal disease. 14 [DOI] 10.1177/1759720X221096381. [PMID] 35586516.
2021
Post-hoc analysis of pegloticase pivotal trials in chronic refractory gout: relationship between fluctuations in plasma urate levels and acute flares.
Clinical and experimental rheumatology. 39(5):1085-1092 [DOI] 10.55563/clinexprheumatol/b7jjnb. [PMID] 33427618.
2021
Towards development of core domain sets for short term and long term studies of calcium pyrophosphate crystal deposition (CPPD) disease: A framework paper by the OMERACT CPPD working group.
Seminars in arthritis and rheumatism. 51(4):946-950 [DOI] 10.1016/j.semarthrit.2021.04.019. [PMID] 34140183.
2020
Development of a multivariable improvement measure for gout.
Arthritis research & therapy. 22(1) [DOI] 10.1186/s13075-020-02254-4. [PMID] 32600452.
2020
Gout management and outcomes during the COVID-19 pandemic: a cross-sectional internet survey.
Therapeutic advances in musculoskeletal disease. 12 [DOI] 10.1177/1759720X20966124. [PMID] 33133248.
2020
Management of Gout in the United States: A Claims-based Analysis.
ACR open rheumatology. 2(3):180-187 [DOI] 10.1002/acr2.11121. [PMID] 32114719.
2020
Patient Perceptions of Gout Management Goals: A Cross-sectional Internet Survey.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 26(4):129-133 [DOI] 10.1097/RHU.0000000000000981. [PMID] 32453285.
2020
Response to the 2020 American College of Rheumatology Guideline for the Management of Gout: Comment on the Article by FitzGerald et al.
Arthritis care & research. 72(10):1506-1507 [DOI] 10.1002/acr.24379. [PMID] 32702211.
2019
Evaluation of Proposed Criteria for Remission and Evidence-Based Development of Criteria for Complete Response in Patients With Chronic Refractory Gout.
ACR open rheumatology. 1(4):236-243 [DOI] 10.1002/acr2.1025. [PMID] 31777799.
2019
Experience of finding footwear and factors contributing to footwear choice in people with gout: a mixed methods study using a web-based survey.
Journal of foot and ankle research. 12 [DOI] 10.1186/s13047-018-0313-y. [PMID] 30636975.
2019
Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout.
Annals of the rheumatic diseases. 78(11):1592-1600 [DOI] 10.1136/annrheumdis-2019-215933. [PMID] 31501138.
2019
Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout.
Arthritis care & research. 71(3):427-434 [DOI] 10.1002/acr.23607. [PMID] 29799677.
2018
EULAR gout treatment guidelines by Richette et al.: uric acid and neurocognition.
Annals of the rheumatic diseases. 77(4) [DOI] 10.1136/annrheumdis-2017-211418. [PMID] 28347993.
2017
Renal dosing of allopurinol results in suboptimal gout care.
Annals of the rheumatic diseases. 76(1) [DOI] 10.1136/annrheumdis-2016-210352. [PMID] 27582422.
2016
A cross-sectional internet-based patient survey of the management strategies for gout.
BMC complementary and alternative medicine. 16 [DOI] 10.1186/s12906-016-1067-3. [PMID] 26931313.
2016
Overview of Serum Uric Acid Treatment Targets in Gout: Why Less Than 6 mg/dL?
Postgraduate medicine. 128(7):706-15 [DOI] 10.1080/00325481.2016.1221732. [PMID] 27558643.
2015
2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
Annals of the Rheumatic Diseases. 74(10):1789-98 [DOI] 10.1136/annrheumdis-2015-208237. [PMID] 26359487.
2015
2015 Gout Classification Criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
Arthritis & rheumatology (Hoboken, N.J.). 67(10):2557-68 [DOI] 10.1002/art.39254. [PMID] 26352873.
2015
An internet survey of common treatments used by patients with gout including cherry extract and juice and other dietary supplements.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 21(4):225-6 [DOI] 10.1097/RHU.0000000000000246. [PMID] 26010189.
2014
Application of the OMERACT filter to measures of core outcome domains in recent clinical studies of acute gout.
The Journal of rheumatology. 41(3):574-80 [DOI] 10.3899/jrheum.131245. [PMID] 24429178.
2014
Emerging therapies for gout.
Rheumatic diseases clinics of North America. 40(2):375-87 [DOI] 10.1016/j.rdc.2014.01.013. [PMID] 24703353.
2014
OMERACT endorsement of measures of outcome for studies of acute gout.
The Journal of rheumatology. 41(3):569-73 [DOI] 10.3899/jrheum.131246. [PMID] 24334651.
2013
A delphi exercise to identify characteristic features of gout – opinions from patients and physicians, the first stage in developing new classification criteria.
The Journal of rheumatology. 40(4):498-505 [DOI] 10.3899/jrheum.121037. [PMID] 23418379.
2012
2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.
Arthritis care & research. 64(10):1431-46 [DOI] 10.1002/acr.21772. [PMID] 23024028.
2012
2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.
Arthritis care & research. 64(10):1447-61 [DOI] 10.1002/acr.21773. [PMID] 23024029.
2012
Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials.
The Journal of rheumatology. 39(7):1450-7 [DOI] 10.3899/jrheum.111375. [PMID] 22660805.
2011
2011 recommendations for the diagnosis and management of gout and hyperuricemia.
The Physician and sportsmedicine. 39(4):98-123 [DOI] 10.3810/psm.2011.11.1946. [PMID] 22293773.
2011
2011 Recommendations for the diagnosis and management of gout and hyperuricemia.
Postgraduate medicine. 123(6 Suppl 1):3-36 [DOI] 10.3810/pgm.2011.11.2511. [PMID] 22156509.
2011
Bringing it all together: a novel approach to the development of response criteria for chronic gout clinical trials.
The Journal of rheumatology. 38(7):1467-70 [DOI] 10.3899/jrheum.110274. [PMID] 21724718.
2011
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
JAMA. 306(7):711-20 [DOI] 10.1001/jama.2011.1169. [PMID] 21846852.
2011
Patient-reported outcomes in chronic gout: a report from OMERACT 10.
The Journal of rheumatology. 38(7):1452-7 [DOI] 10.3899/jrheum.110271. [PMID] 21724715.
2011
Quality of care in patients with gout: why is management suboptimal and what can be done about it?
Current rheumatology reports. 13(2):154-9 [DOI] 10.1007/s11926-010-0154-6. [PMID] 21161617.
2011
Serum urate as a soluble biomarker in chronic gout-evidence that serum urate fulfills the OMERACT validation criteria for soluble biomarkers.
Seminars in arthritis and rheumatism. 40(6):483-500 [DOI] 10.1016/j.semarthrit.2010.09.003. [PMID] 21056459.
2011
Serum urate in chronic gout–will it be the first validated soluble biomarker in rheumatology?
The Journal of rheumatology. 38(7):1462-6 [DOI] 10.3899/jrheum.110273. [PMID] 21724717.
2011
Tophus measurement as an outcome measure for clinical trials of chronic gout: progress and research priorities.
The Journal of rheumatology. 38(7):1458-61 [DOI] 10.3899/jrheum.110272. [PMID] 21724716.
2011
Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy.
Journal of medical economics. 14(1):10-5 [DOI] 10.3111/13696998.2010.540874. [PMID] 21138339.
2010
Chronic Gout: Epidemiology, Disease Progression, Treatment and Disease Burden
Current Medical Research and Opinion. 26(12):2813-2821 [DOI] 10.1185/03007995.2010.533647. [PMID] 21050059.
2010
Managing gout in the primary care setting: what you and your patients need to know.
The American journal of medicine. 123(8) [DOI] 10.1016/j.amjmed.2010.06.005. [PMID] 20670699.
2010
Preventing and treating acute gout attacks across the clinical spectrum: a roundtable discussion.
Cleveland Clinic journal of medicine. 77 Suppl 2:S2-25 [DOI] 10.3949/ccjm.77.s2.01. [PMID] 20516241.
2009
Febuxostat: a new treatment for hyperuricaemia in gout.
Rheumatology (Oxford, England). 48 Suppl 2:ii15-ii19 [DOI] 10.1093/rheumatology/kep088. [PMID] 19447778.
2009
Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link?
Arthritis research & therapy. 11(4) [DOI] 10.1186/ar2761. [PMID] 19725932.
2009
Outcome Domains for Studies of Acute and Chronic Gout
The Journal of rheumatology. 36(10):2342-2345 [DOI] 10.3899/jrheum.090370. [PMID] 19820223.
2009
Progress in measurement instruments for acute and chronic gout studies.
The Journal of rheumatology. 36(10):2346-55 [DOI] 10.3899/jrheum.090371. [PMID] 19820224.
2009
The role of hyperuricemia in vascular disorders.
Current opinion in rheumatology. 21(2):132-7 [DOI] 10.1097/BOR.0b013e3283257b96. [PMID] 19339923.
2009
Toward a valid definition of gout flare: results of consensus exercises using Delphi methodology and cognitive mapping.
Arthritis and rheumatism. 61(4):535-43 [DOI] 10.1002/art.24166. [PMID] 19333981.
2008
Clinical Homogeneity and Syndromic Characteristics of Treatment Failure Gout (Tfg) in Four Independent Cohorts
Arthritis and Rheumatism. 58:S180-S181
2008
Efficacy and Safety of Intravenous (Iv) Pegloticase (Pgl) in Subjects With Treatment Failure Gout (Tfg): Phase 3 Results From Gout1 and Gout2
Arthritis and Rheumatism. 58:S400-S401
2008
Febuxostat – a Viewpoint
Annals of epidemiology. 68(2):1875-1876 [DOI] 10.2165/00003495-200868130-00007. [PMID] 24342030.
2008
Febuxostat : a viewpoint by N. Lawrence Edwards.
Drugs. 68(13):1875-6 [PMID] 18729540.
2008
Health-Related Quality-Of-Life (Hrqol) of Patients With Refractory Gout (Refractory-Gout) and Us Veterans Administration Patients With Gout and Comorbities (Va-Gout) Is Poor and Comparable To That in Other Severe Chronic Conditions
Arthritis and Rheumatism. 58
2008
Immunoreactivity and Clinical Response To Pegloticase (Pgl): Pooled Data From Gout1 and Gout2, Pgl Phase 3 Randomized, Double Blind, Placebo-Controlled Trials
Arthritis and Rheumatism. 58
2008
Immunoreactivity and Clinical Response To Pegloticase (Pgl): Pooled Data From Gout1 and Gout2, Pgl Phase 3 Randomized, Double Blind, Placebo-Controlled Trials
Arthritis and Rheumatism. 58
2008
Improvement in Health-Related Quality of Life (Hrql) and Disability Index in Treatment Failure Gout (Tfg) After Pegloticase (Pgl) Therapy: Pooled Results From Gout1 and Gout2, Phase 3, Randomized Double Blind, Placebo (Pbo)-Controlled Trials
Arthritis and Rheumatism. 58
2008
In defense of research into the crystal induced arthropathies.
The Journal of rheumatology. 35(11):2278-9; author reply 2279 [DOI] 10.3899/jrheum.080599. [PMID] 19004057.
2008
The role of hyperuricemia and gout in kidney and cardiovascular disease.
Cleveland Clinic journal of medicine. 75 Suppl 5:S13-6 [PMID] 18822470.
2008
Tophus Response To Pegloticase (Pgl) Therapy: Pooled Results From Gout1 and Gout2, Pgl Phase 3 Randomized, Double Blind, Placebo-Controlled Trials
Arthritis and Rheumatism. 58
2008
Treatment-failure gout: a moving target.
Arthritis and rheumatism. 58(9):2587-90 [DOI] 10.1002/art.23803. [PMID] 18759307.
2008
Work Productivity Loss Due To Flares in Treatment-Failure Gout (Tfg)
Arthritis and Rheumatism. 58
2007
Outcome evaluations in gout.
The Journal of rheumatology. 34(6):1381-5 [PMID] 17552064.
2006
Case 6: maintenance therapy for simple intermittent gout.
The American journal of medicine. 119(11 Suppl 1):S20-2 [PMID] 17059908.
2006
Case 7: differential diagnosis of advanced gout.
The American journal of medicine. 119(11 Suppl 1):S23-4 [PMID] 17059909.
2006
Case 9: initiation of urate-lowering therapy for advanced gout complicated by chronic renal insufficiency.
The American journal of medicine. 119(11 Suppl 1):S29-31 [PMID] 17059911.
2006
Magnetic resonance imaging in the quantitative assessment of gouty tophi.
International journal of clinical practice. 60(4):408-14 [PMID] 16620352.
2005
Treatment of osteoarthritis.
Southern medical journal. 98(2):205-9 [PMID] 15759951.
1996
Magnetic resonance imaging of tophaceous gout in the hands and wrists.
Seminars in arthritis and rheumatism. 25(4):282-9 [PMID] 8834016.
1995
Axial skeletal changes in paralysed patients may mimic ankylosing spondylitis.
British journal of rheumatology. 34(2):174-7 [PMID] 7704467.
1995
Clinical pathogenesis and diagnosis of osteoarthritis.
Contemporary internal medicine. 7(6):13-6, 21 [PMID] 10150438.
1995
New insights into gouty arthritis.
Contemporary internal medicine. 7(1):55-64 [PMID] 10150333.
1993
A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation.
The EMBO journal. 12(9):3551-8 [PMID] 8253080.
1991
Drugs to lower uric acid levels. How to avoid misuse in gouty arthritis.
Postgraduate medicine. 89(2):111-3, 116 [PMID] 1990384.
1990
Magnetic resonance imaging in patients with inflammatory arthritis of the knee.
Clinical rheumatology. 9(1):73-83 [PMID] 2335054.
1989
Cerebrospinal fluid cyclic nucleotide alterations in the Lesch-Nyhan syndrome.
Advances in experimental medicine and biology. 253A:181-4 [PMID] 2560331.
1989
Metabolism of guanosine and its C-8 substituted analogues in human lymphocyte cytoplasm.
Advances in experimental medicine and biology. 253B:285-9 [PMID] 2610119.
1989
Profile of a meeting: how abstracts are written and reviewed.
The Journal of rheumatology. 16(2):145-7 [PMID] 2746562.
1988
‘Rhupus’ syndrome.
Archives of internal medicine. 148(7):1633-6 [PMID] 3382309.
1988
Vasculitis associated with malignancy. Experience with 13 patients and literature review.
Medicine. 67(4):220-30 [PMID] 3292873.
1987
Central nervous system vasculitis.
Annals of allergy. 58(3):162-3, 209 [PMID] 3826768.
1987
Silicone and rheumatic diseases.
Seminars in arthritis and rheumatism. 17(2):112-8 [PMID] 3334283.
1987
Technetium pyrophosphate muscle scans in inflammatory muscle disease.
British journal of rheumatology. 26(4):267-9 [PMID] 3038250.
1986
Is running associated with degenerative joint disease?
JAMA. 255(9):1152-4 [PMID] 3945034.
1986
Purine and monoamine metabolites in cerebrospinal fluid.
Advances in experimental medicine and biology. 195 Pt B:53-6 [PMID] 2429511.
1986
The effect of allopurinol on cerebral spinal fluid (CSF) purines in hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency syndromes.
Advances in experimental medicine and biology. 195 Pt A:465-9 [PMID] 3728180.
1985
Lesch-Nyhan syndrome: CSF neurotransmitter abnormalities.
Neurology. 35(6):907-11 [PMID] 2582310.
1984
Enzyme replacement in the Lesch-Nyhan syndrome with long-term erythrocyte transfusions.
Advances in experimental medicine and biology. 165 Pt A:23-6 [PMID] 6720384.
1984
Plasma membrane 5′-nucleotidase and other purine enzymes in murine lymphocytes.
Advances in experimental medicine and biology. 165 Pt B:129-32 [PMID] 6326495.
1983
The diagnosis and management of gouty arthritis.
Comprehensive therapy. 9(9):14-9 [PMID] 6627900.
1980
Altered purine and pyrimidine metabolism in erythrocytes with purine nucleoside phosphorylase deficiency.
Biochemical genetics. 18(3-4):221-34 [PMID] 6160848.
1980
Hypoxanthine salvage in man: its importance in urate overproduction in the Lesch-Nyhan syndrome.
Advances in experimental medicine and biology. 122A:301-6 [PMID] 7424648.
1979
Overproduction of uric acid in hypoxanthine-guanine phosphoribosyltransferase deficiency. Contribution by impaired purine salvage.
The Journal of clinical investigation. 63(5):922-30 [PMID] 447834.

Education

Fellowship – Rheumatology
1979 · University of Michigan
Residency – Internal Medicine
1976 · Creighton University
Medical School
1973 · University of Miami

Contact Details

Phones:
Business:
(352) 265-0239
Emails:
Business:
edwarnl@ufl.edu
Addresses:
Business Mailing:
PO Box 100277
GAINESVILLE FL 32610
Business Street:
J. HILLIS MILLER HEALTH CENTER ROOM 4102
J. HILLIS MILLER HEALTH CENTER
GAINESVILLE FL 326100001